Advancing Treatments for Rare Eye Diseases in Europe
Restore Vision is a project funded by the European Commission aiming to develop and test new treatments for 7 rare eye diseases (REDs). The consortium joins 10 European key players on rare eye diseases and is led by University of Galway.
About Restore Vision
+30 million
people suffer from blindness and visual impairment
About Restore Vision
Over the the next 4 years (2023-2027) the Restore Vision consortium will explore new treatments for 7 REDs by repurposing existing generic drugs, developing new theurapeutic compounds, and conducting pioneering clinical trials to ensure their safety and effectiveness.
Learn more about our work
Project in numbers
0
Years (2023-2027)
0
Partners
0
EUR in funding
0
EU Countries
0
Work packages
News
Read Restore Vision’s latest news.
06 February 2025
Healing the cornea: the therapeutic potential of Mesenchymal Stromal Cells and their Extracellular Vesicles
In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.
Read more
30 January 2025
New article: Are inactive ingredients in eye drops safe? A closer look at excipients safety, function an regulation.
Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.
Read more
17 January 2025
Restore Vision’s first review meeting
On January, 30. The RESTORE VISION team held its first review meeting to assess project progress and discuss plans for the upcoming year.
Read more
11 December 2024
Partecipa al nostro studio presso l’Ospedale San Raffaele di Milano!
Aiutaci a far progredire la ricerca sulle malattie oculari rare!
Read more
11 December 2024
Participate in our study in Milan, Italy!
Join our study in Milan, Italy and help us advance research on rare eye conditions!
Read more
Interested in Restore vision?
Stay informed about our efforts to combat rare eye diseases and bring new hope to those affected by visual impairment by subscribing to our newsletter for updates on our latest treatments and research.